A new algorithm was able to accurately predict death in 96% of patients with End-Stage Liver Disease (ESLD) and is designed to help physician decision-making in ESLD.
The algorithm is based on a combination of pre-morbid liver function and Acute-on-Chronic Liver Failure (ACLF) grade, and allows physicians to help determine patients who were likely to benefit from intensive care unit (ICU) treatment compared with those who would not.
‘The new algorithm is based on commonly used scales to assess disease severity including Child-Pugh Score, Model for End-Stage Liver Disease and the CLIF-SOFA-score.’
AdvertisementACLF is a relatively common syndrome and occurs in 31% of hospitalised patients with cirrhosis who have an acute complication of their liver disease. In these patients, ACLF is the most common cause of death.
ACLF is distinct from severe liver damage (decompensated cirrhosis) as organ failure and mortality rates are high. Furthermore, patients with ALCF tend to be younger, have more scarring of the liver as a result of alcohol, and have less liver scarring as a result of Hepatitis C virus, compared to those with decompensated cirrhosis.
"When patients are very ill, physicians must ensure that our concern for the patient should not result in the recommendation of treatment that will be of no benefit," said Dr Katrine Lindvig, Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark and lead study author. "We now have well validated data that allows us to more accurately predict who is likely to benefit from treatment compared with previous measures."
Researchers collected data on 354 patients hospitalised with cirrhosis from centres in Belgium, Austria and Denmark. The new algorithm, based on commonly used scales to assess disease severity including Child-Pugh Score, Model for End-Stage Liver Disease (MELD) and the CLIF-SOFA-score, separated patients into two groups: those likely to benefit and survive ICU and those who were unlikely to benefit or survive intensive care therapy if needed.
The algorithm correctly predicted outcomes in 96% of cases and an odds ratio (a measure of association) for death of 4.7 (2.50-9.05 95% confidence interval).
"If the first duty of a physician is to do no harm, then we must continually review our decision-making tools and favour those that have the highest predictive value of treatment success and - importantly - treatment failure. This study adds to our knowledge of existing, well-recognised scoring systems, and provides an interesting approach for review and wider discussion by the liver community," said Professor Tom Hemming Karlsen, EASL Vice-Secretary.
PParasitic Worms may Help Treat Irritable Bowel Disease Type 2 Diabetes Drug for Non-alcoholic Fatty Liver Disease M
You May Also Like